TGF-β Suppresses Tumor Progression in Colon Cancer by Inhibition of IL-6 trans-Signaling

Abstract Alterations of TGF-β signaling have been described in colorectal cancer, although the molecular consequences are largely unknown. By using transgenic mice overexpressing TGF-β or a dominant-negative TGF-βRII, we demonstrate that TGF-β signaling in tumor infiltrating T lymphocytes controls the growth of dysplastic epithelial cells in experimental colorectal cancer, as determined by histology and a novel system for high-resolution chromoendoscopy. At the molecular level, TGF-β signaling in T cells regulated STAT-3 activation in tumor cells via IL-6. IL-6 signaling required tumor cell-derived soluble IL-6R rather than membrane bound IL-6R and suppression of such TGF-β-dependent IL-6 trans -signaling prevented tumor progression in vivo. Taken together, our data provide novel insights into TGF-β signaling in colorectal cancer and suggest novel therapeutic approaches for colorectal cancer based on inhibition of TGF-β-dependent IL-6 trans -signaling.

[1]  T. S. Wilkinson,et al.  Il-6 and its soluble receptor orchestrate a temporal switch in the pattern of leukocyte recruitment seen during acute inflammation. , 2001, Immunity.

[2]  David C. Lee,et al.  Tumor Necrosis Factor-α Converting Enzyme (TACE) Regulates Epidermal Growth Factor Receptor Ligand Availability* , 2002, The Journal of Biological Chemistry.

[3]  P. Wallace,et al.  Central role of IL-6 receptor signal-transducing chain gp130 in activation of L-selectin adhesion by fever-range thermal stress. , 2004, Immunity.

[4]  A. Roberts,et al.  Factors involved in the differentiation of TGF-beta-producing cells from naive CD4+ T cells: IL-4 and IFN-gamma have opposing effects, while TGF-beta positively regulates its own production. , 1998, Journal of immunology.

[5]  S. Takeno,et al.  Prognostic significance of CD8+ T cell and macrophage peritumoral infiltration in colorectal cancer. , 2003, Oncology reports.

[6]  J. Baselga,et al.  TACE is required for the activation of the EGFR by TGF‐α in tumors , 2003 .

[7]  Markus F Neurath,et al.  IL-6 trans-signaling: the heat is on. , 2004, Immunity.

[8]  J. Wang,et al.  Soluble interleukin 6 receptor (sIL-6R) mediates colonic tumor cell adherence to the vascular endothelium: a mechanism for metastatic initiation? , 2002, The Journal of surgical research.

[9]  M. Tomlinson,et al.  TGF‐β1 down‐regulates Th2 development and results in decreased IL‐4‐induced STAT6 activation and GATA‐3 expression , 2000 .

[10]  L. Pelosio,et al.  Prognostic significance of circulating IL-10 and IL-6 serum levels in colon cancer patients undergoing surgery. , 2002, Clinical immunology.

[11]  B. Jenkins,et al.  Reciprocal regulation of gastrointestinal homeostasis by SHP2 and STAT-mediated trefoil gene activation in gp130 mutant mice , 2002, Nature Medicine.

[12]  T. Naka,et al.  The paradigm of IL-6: from basic science to medicine , 2002, Arthritis research.

[13]  K. Kinzler,et al.  Mutational inactivation of transforming growth factor beta receptor type II in microsatellite stable colon cancers. , 1999, Cancer research.

[14]  A. Roberts,et al.  Targeted disruption of SMAD3 results in impaired mucosal immunity and diminished T cell responsiveness to TGF‐β , 1999, The EMBO journal.

[15]  A. Jemal,et al.  Annual report to the nation on the status of cancer, 1975-2000, featuring the uses of surveillance data for cancer prevention and control. , 2003, Journal of the National Cancer Institute.

[16]  R. Coffey,et al.  Production of transforming growth factors by human colon cancer lines. , 1986, Cancer Research.

[17]  G. Ciliberto,et al.  Role of IL-6 and its soluble receptor in induction of chemokines and leukocyte recruitment. , 1997, Immunity.

[18]  M. Neurath,et al.  Constitutive p40 promoter activation and IL-23 production in the terminal ileum mediated by dendritic cells. , 2003, The Journal of clinical investigation.

[19]  S. Rose-John,et al.  A bioactive designer cytokine for human hematopoietic progenitor cell expansion , 1997, Nature Biotechnology.

[20]  P. Schirmacher,et al.  Impairment of TGF-beta signaling in T cells increases susceptibility to experimental autoimmune hepatitis in mice. , 2003, American journal of physiology. Gastrointestinal and liver physiology.

[21]  M. Neurath,et al.  Blockade of interleukin 6 trans signaling suppresses T-cell resistance against apoptosis in chronic intestinal inflammation: Evidence in Crohn disease and experimental colitis in vivo , 2000, Nature Medicine.

[22]  P. Heinrich,et al.  Soluble receptors for cytokines and growth factors: generation and biological function. , 1994, The Biochemical journal.

[23]  L. Glimcher,et al.  Lineage commitment in the immune system: the T helper lymphocyte grows up. , 2000, Genes & development.

[24]  S. Akira Roles of STAT3 defined by tissue-specific gene targeting , 2000, Oncogene.

[25]  J. Grötzinger,et al.  The Soluble Interleukin‐6 Receptor a , 1995, Annals of the New York Academy of Sciences.

[26]  M. Neurath,et al.  The role of Th1/Th2 polarization in mucosal immunity , 2002, Nature Medicine.

[27]  S. Szabo,et al.  Transcriptional regulation of Th1/Th2 polarization. , 2000, Immunology today.

[28]  Yuan‐Chang Chung,et al.  Serum interleukin‐6 levels reflect the disease status of colorectal cancer , 2003, Journal of surgical oncology.

[29]  Simon A. Jones,et al.  The soluble interleukin 6 receptor: mechanisms of production and implications in disease , 2001, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[30]  Kenneth M. Murphy,et al.  Decision making in the immune system: The lineage decisions of helper T cells , 2002, Nature Reviews Immunology.

[31]  Takuji Tanaka,et al.  A novel inflammation‐related mouse colon carcinogenesis model induced by azoxymethane and dextran sodium sulfate , 2003, Cancer science.

[32]  A. Hoeflich,et al.  Interleukin-6 stimulates clonogenic growth of primary and metastatic human colon carcinoma cells. , 2000, Cancer letters.

[33]  T. Ohkusa,et al.  Promotion of colorectal neoplasia in experimental murine ulcerative colitis. , 1996, Gut.